Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Consensus PT from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have earned a consensus rating of "Buy" from the seven ratings firms that are covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $28.83.

A number of research analysts have weighed in on IMNM shares. Piper Sandler reduced their target price on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Thursday, November 14th. Stephens assumed coverage on shares of Immunome in a research report on Friday, November 8th. They issued an "overweight" rating and a $30.00 price objective for the company. Finally, Wedbush reaffirmed an "outperform" rating and set a $33.00 price objective on shares of Immunome in a research note on Monday.

Immunome Trading Up 7.8 %

Shares of NASDAQ IMNM traded up $0.73 during mid-day trading on Wednesday, hitting $10.11. The company had a trading volume of 669,686 shares, compared to its average volume of 627,610. Immunome has a 1 year low of $8.97 and a 1 year high of $30.96. The company has a market capitalization of $631.04 million, a price-to-earnings ratio of -1.25 and a beta of 1.90. The stock's 50-day moving average price is $11.65 and its 200-day moving average price is $12.96.

Insider Transactions at Immunome

In related news, insider Robert Lechleider acquired 15,805 shares of the stock in a transaction dated Thursday, November 21st. The shares were purchased at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the transaction, the insider now owns 15,805 shares in the company, valued at $149,831.40. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Clay B. Siegall bought 66,057 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The stock was bought at an average price of $9.54 per share, with a total value of $630,183.78. Following the completion of the transaction, the chief executive officer now directly owns 485,693 shares of the company's stock, valued at $4,633,511.22. This represents a 15.74 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 102,862 shares of company stock valued at $978,045. 8.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Immunome

A number of large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its position in shares of Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock valued at $131,000 after purchasing an additional 918 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock worth $359,000 after buying an additional 1,520 shares during the last quarter. AQR Capital Management LLC boosted its stake in Immunome by 34.6% in the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock worth $194,000 after buying an additional 4,129 shares in the last quarter. Cerity Partners LLC grew its position in Immunome by 10.5% during the third quarter. Cerity Partners LLC now owns 53,103 shares of the company's stock valued at $776,000 after acquiring an additional 5,043 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Immunome during the second quarter worth approximately $81,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.